PF-08653944

PF-08653944 (berobenatide, formerly MET-097i) is Pfizer's lead obesity asset, acquired through the Metsera deal that closed in late 2025 - not an internally-developed compound as occasionally framed. It is an ultra-long-acting, fully-biased GLP-1 receptor agonist administered by subcutaneous injection, with both once-weekly and once-monthly maintenance regimens in Phase 3. The Phase 3 VESPER program includes NCT07311850 (VESPER-4, weekly in obesity without T2D, n≈3,501) and NCT07400653 (Phase 3 in obesity plus T2D, n=999, primary endpoint percent change in body weight from baseline). Three Phase 1 supporting studies are running: pharmacokinetics (PK, NCT07400679, n=54), hepatic impairment (NCT07519135, n=26), and gastric emptying with an acetaminophen tracer (NCT07508241, n=20). Pfizer paid $47.50/share at closing plus contingent value rights of up to $20.65/share - roughly a $7.0B enterprise value with up to ~$10B including CVRs after a contested bidding war with Novo Nordisk. The strategic context is heavy: Pfizer discontinued its prior oral GLP-1 candidate danuglipron on April 14, 2025, after a single asymptomatic case of potential drug-induced liver injury, which is why berobenatide - injectable, structurally unrelated to danuglipron - is now the program. [1][2][3][4][5][6][7][8]

Phase 3 (multiple key studies recruiting). Subcutaneous injectable peptide. Phase 2b data have been disclosed: VESPER-1 (NCT06712836) reported placebo-subtracted weight loss of up to 14.1% at 28 weeks (1.2 mg once-weekly), with individual responses as high as 26.5%; VESPER-3 reported up to 12.3% placebo-adjusted weight loss in patients who switched from weekly to monthly maintenance dosing. The Phase 1 PK study (NCT07400679) is active but not recruiting, meaning enrollment is complete and Pfizer is in follow-up. The hepatic impairment and gastric emptying studies are still recruiting. No FDA breakthrough therapy, fast track, or orphan designations are publicly disclosed for berobenatide as of mid-2026. Expected primary completion for NCT07400653 is not posted on ClinicalTrials.gov; based on enrollment opening in mid-2026 and typical 48-72 week endpoint windows for obesity/T2D Phase 3 trials, a 2028-2029 primary completion window is the defensible estimate. A regulatory filing before 2028 is unlikely without an interim analysis. Pfizer's 2024 revenue base of ~$63B gives the program runway through readout. [1][2][3][9][10][11]

Berobenatide is a fully-biased, ultra-long-acting GLP-1 receptor agonist - Pfizer and Metsera have disclosed the mechanism publicly. GLP-1 (glucagon-like peptide-1) is a hormone released by the gut after eating that signals the brain to reduce appetite and slows the stomach from emptying into the small intestine; mimicking it pharmacologically is how drugs like semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound) produce weight loss. The 'fully-biased' design refers to selective signaling through G-protein pathways while minimizing β-arrestin recruitment, which preclinically is associated with reduced GI side effects and durable receptor responsiveness. The dedicated gastric emptying study (NCT07508241) uses acetaminophen as a tracer to measure how quickly the stomach passes contents into the small intestine - a standard pharmacodynamic confirmation for incretin-pathway drugs. The biology is the most validated target in metabolic disease: tirzepatide produced ~22% mean weight loss in non-diabetic obese patients (SURMOUNT-1) and semaglutide ~15% (STEP-1). Combined GLP-1 sales from Novo and Lilly exceeded $50B in 2024. The mechanism case is unimpeachable. The execution case carries danuglipron history, but berobenatide is a different molecule and a different route (injectable peptide vs. oral small molecule). [4][9][12][13][14]

NCT07400653 is a Phase 3 study in ~999 adults with overweight/obesity plus type 2 diabetes (T2D), primary endpoint percent change in body weight from baseline. Berobenatide is administered by subcutaneous injection. Choosing weight loss rather than HbA1c (the blood sugar control marker used to measure long-term glycemic management) as the primary endpoint in a T2D population is a deliberate framing - it positions berobenatide against tirzepatide on Lilly's chosen battlefield rather than competing on glycemic control alone. Tirzepatide delivered ~14% weight loss in SURPASS-2 (T2D) and Pfizer presumably needs to match or beat that to justify market entry. NCT07311850 (VESPER-4) is the companion Phase 3 in obesity without T2D, n≈3,501, once-weekly dosing. The supporting Phase 1 package is textbook regulatory work: standard pharmacokinetics (PK, the study of how the drug is absorbed, distributed, and cleared from the body) (NCT07400679, n=54), hepatic impairment (NCT07519135, n=26), and gastric emptying with acetaminophen tracer (NCT07508241, n=20). The comparator arm in NCT07400653 is not publicly specified in the trial record summary, but placebo is the standard for an obesity Phase 3; a head-to-head against semaglutide or tirzepatide would be a stronger commercial signal. The Phase 2b data (VESPER-1 and VESPER-3) anchor dose selection for the Phase 3 program - Pfizer is not jumping from Phase 1 PK to Phase 3 on conviction alone. [1][2][3][4][9][10][11]

Our model gives this drug a 38% chance of eventual approval. That starts from the historical approval rate for Phase 3 drugs in this area-about 66%-then adjusts based on ten specific facts about the trial and sponsor. The estimate is pulled up by the trial's blinding design and the sponsor's strong approval track record, and pulled down by smaller-than-typical enrollment and weak earlier-phase results. The remaining factors are close to average for this stage, so they don't move the number much in either direction.

Safety: Danuglipron was discontinued April 14, 2025, after a single asymptomatic case of potential drug-induced liver injury in a dose-optimization study. Pfizer noted that the overall frequency of liver enzyme elevations across the >1,400-participant danuglipron safety database was in-line with approved agents in the class. Berobenatide is a different molecule (injectable peptide vs. oral small molecule) and the hepatic risk profile is not directly transferable, but Pfizer's dedicated hepatic impairment study (NCT07519135) and extensive PK package signal disciplined hepatic-safety surveillance. Any liver enzyme elevations in the Phase 3 will be magnified by investor memory. Efficacy: tirzepatide's ~22% weight loss in non-diabetic obese patients is the benchmark. Berobenatide's Phase 2b ceiling (~14.1% placebo-subtracted at 28 weeks) is competitive but not class-leading; longer Phase 3 exposure will need to show continued weight loss. Retatrutide (Lilly's triple agonist) hit ~24% at 48 weeks in Phase 2 - by the time berobenatide could launch (2029+), the bar will be higher. Commercial: obesity drug pricing is under pressure from cash-pay competition, Medicare coverage debate, and compounder dynamics. Strategic: monthly maintenance dosing is the differentiated patient-preference angle; if Phase 3 monthly arms don't sustain the Phase 2b crossover signal, the unique commercial pitch collapses. Manufacturing: berobenatide is a peptide, so scale-up depends on solid-phase peptide synthesis capacity that is already constrained industry-wide. [4][5][6][9][12][13][16]

Worth watching, medium conviction now that Phase 2b data are public. The signal that would move this from credible to high-conviction: a Phase 3 weight-loss readout ≥17-18% at 52+ weeks with no liver enzyme elevations, plus durability data showing monthly maintenance holds at least 80% of weekly induction weight loss. That would put berobenatide in the same conversation as tirzepatide and put real pressure on Novo's monthly franchise plans. The signal that would kill it: any hepatic safety flag in NCT07519135 or NCT07400653 - Pfizer has already lived through that exact failure mode with danuglipron and the market will not be charitable. The right moment to check back is Pfizer's Q4 2026 or Q1 2027 earnings call, where management typically discusses obesity pipeline progress, and the first VESPER-4 interim readouts if they're disclosed. Pfizer's $63B revenue base funds the program through readout regardless of intermediate signals. The strategic question isn't whether berobenatide works - Phase 2b says it does - it's whether ~14% Phase 2b weight loss scales into Phase 3 efficacy strong enough to take share in a market that may consolidate around Novo and Lilly before Pfizer ever launches in 2029. The Metsera acquisition cost Pfizer roughly $7B upfront at closing (potentially up to ~$10B with CVRs). The Phase 3 program now has to justify that price. [5][6][7][8][17]